About
Mel Spigelman joined the Wellington Partners Life Science team as a Venture Partner in 2005. He advises on clinical development, regulatory affairs and strategic decisions. Since 2003, Mel has been serving as R&D Director of the New York-based Global Alliance for TB Drug Development. This not-for-profit organization is dedicated to the rising challenge of innovative treatment for TB. He has also been involved in venture capital since 2002, as an independent advisor to U.S. and European VC firms, including Wellington. From 1989 to 2001, Mel held various key positions at BASF Pharma, culminating in Vice President Global Clinical Centers. Here, he established a track record in global development and registration of drugs in the indications of cardiovascular medicine, endocrinology, oncology, and immunology. Mel holds a B.A. in engineering and an MD from the Mount Sinai School of Medicine, New York, where he also worked as Assistant Professor for several years.
Position in the VCSift Database
- • 6 investors at Wellington Partners are tracked.
- • 421 investors hold the Venture Partner role in VCSift. Melvin Spigelman is one of them.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- New York, US
Contact Information
Find more investors like Melvin
Search Investors